IPS Selected to Build a Global Rare Disease Community - September 2022

IPS launch another global community in rare diseases sector.

IPS has been selected by one of the world’s largest, rare disease pharmaceutical companies to build another global specialist community. The community will provide members with high quality information, accredited education and to collaborate and share best practice.

In addition, community members will also have the opportunity to opt-in and participate in digital advisory boards and insight gathering research.

‍